Unanticipated improvement in seizure control in drug-resistant epilepsy-real world observations

被引:5
|
作者
Moloney, Patrick B. [1 ]
Costello, Daniel J. [1 ,2 ]
机构
[1] Cork Univ Hosp, Dept Neurol, Cork, Ireland
[2] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland
来源
关键词
Drug-resistant epilepsy; Anti-seizure medication; Unanticipated treatment response; Rational polytherapy; QUALITY-OF-LIFE; ANTIEPILEPTIC DRUGS; ILAE COMMISSION; REMISSION; POPULATION; LACOSAMIDE; OUTCOMES; SURGERY; RELAPSE;
D O I
10.1016/j.seizure.2020.11.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To determine the clinical features and anti-seizure medication (ASM) strategies associated with an unanticipated substantial improvement in seizure control in patients with drug-resistant epilepsy (DRE). Methods: This retrospective analysis of patients attending a tertiary care epilepsy clinic between 2008 and 2017 identified all patients with active DRE (at least 1 seizure per month for 6 months, despite treatment with 2 different ASMs). All treatment interventions were recorded from when DRE was first identified to the end of the study. The primary end points were seizure freedom or meaningful reduction in seizure frequency (greater than 75 %) sustained for at least 12 months after a treatment intervention. Results: Three hundred and twenty-two patients were included in the analysis. Overall, 10 % became seizure free following ASM adjustment and an additional 10 % had a greater than 75 % improvement in seizure control (median follow-up, 4 years). An ASM introduction was ten times more likely than an ASM dose increase to improve seizure control. Combined focal and generalized epilepsy, intellectual disability and prior treatment with more than 5 ASMs were more frequently observed in those with continued pharmacoresistance. ASM responders were more likely to have primary generalized epilepsy. Rational polytherapy (combining ASMs with different mechanisms of action) was almost ubiquitous amongst ASMs responders (95 % taking at least 2 drugs with different mechanistic targets). Of the ASM additions that heralded improved seizure control, 85 % were maintained at submaximal doses. Conclusions: This retrospective analysis of a large number of 'real-world' patients provides evidence to persist with ASM trials in DRE. Early rotation of ASMs if a clinical response is not observed at a substantial dose and rational ASM polytherapy may yield better clinical outcomes in patients with DRE, although a prospective study would need to be conducted to validate these findings.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 50 条
  • [21] Postoperative seizure and developmental outcomes of children with hemimegalencephaly and drug-resistant epilepsy
    Liu, Qingzhu
    Ma, Jiayi
    Yu, Guojing
    Zhang, Qian
    Zhu, Ying
    Wang, Ruofan
    Yu, Hao
    Liu, Chang
    Sun, Yu
    Wang, Wen
    Wang, Shuang
    Ji, Taoyun
    Li, Ming
    Liu, Xiaoyan
    Jiang, Yuwu
    Cai, Lixin
    Wu, Ye
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2021, 92 : 29 - 35
  • [22] Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy
    Bourgeois-Vionnet, Julie
    Ryvlin, Philippe
    Elsensohn, Mad-Helenie
    Michel, Veronique
    Valton, Luc
    Derambure, Philippe
    Frazzini, Valerio
    Hirsch, Edouard
    Maillard, Louis
    Bartolomei, Fabrice
    Biberon, Julien
    Petit, Jerome
    Biraben, Arnaud
    Crespel, Arielle
    Thomas, Pierre
    Lemesle-Martin, Martine
    Convers, Philippe
    Leclercq, Mathilde
    Boulogne, Sebastien
    Roy, Pascal
    Rheims, Sylvain
    EPILEPSY & BEHAVIOR, 2022, 126
  • [23] Beyond seizure freedom: Dissecting long-term seizure control after surgical resection for drug-resistant epilepsy
    Hsieh, Jason K.
    Pucci, Francesco G.
    Sundar, Swetha J.
    Kondylis, Efstathios
    Sharma, Akshay
    Sheikh, Shehryar R.
    Vegh, Deborah
    Moosa, Ahsan N.
    Gupta, Ajay
    Najm, Imad
    Rammo, Richard
    Bingaman, William
    Jehi, Lara
    EPILEPSIA, 2023, 64 (01) : 103 - 113
  • [24] Intentional seizure interruption may decrease the seizure frequency in drug-resistant temporal lobe epilepsy
    Janszky, J
    Szücs, A
    Rasonyi, G
    Schulz, R
    Hoppe, M
    Hollo, A
    Barcs, G
    Kelemen, A
    Halasz, P
    Ebner, A
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2004, 13 (03): : 156 - 160
  • [25] Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States
    Mao, Jianbin
    Takahashi, Koji
    Cheng, Mu
    Xu, Churong
    Boca, Andra
    Song, Yan
    Dandurand, Ann
    EPILEPSIA OPEN, 2024, 9 (04) : 1311 - 1320
  • [26] Real-world antiseizure medication treatment outcomes in drug-resistant focal epilepsy patients
    Hatoum, Hind T.
    Arcona, Steve
    Mao, Jianbin
    Walton, Surrey
    EPILEPSIA OPEN, 2023, 8 (04) : 1556 - 1565
  • [27] Seizure control does not predict hippocampal subfield volume change in children with focal drug-resistant epilepsy
    Wagner, Matthias W.
    Skocic, Jovanka
    Widjaja, Elysa
    NEURORADIOLOGY JOURNAL, 2022, 35 (04): : 454 - 460
  • [28] Factors not considered in the study of drug-resistant epilepsy: Drug-resistant epilepsy: Assessment of neuroinflammation
    Campos-Bedolla, Patricia
    Feria-Romero, Iris
    Orozco-Suarez, Sandra
    EPILEPSIA OPEN, 2022, 7 : S68 - S80
  • [29] Effects of electrical stimulation of the centromedian thalamic nuclei on seizure control in patients with drug-resistant frontal epilepsy
    Valentin, A.
    Alarcon, G.
    Selway, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 307 - 307
  • [30] Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction
    Friedo, Anna-Lena
    Greshake, Benedikt
    Makridis, Konstantin L.
    Straub, Hans-Beatus
    FRONTIERS IN NEUROLOGY, 2023, 14